Mission Street, a specialist investor, developer and operator for the science and innovation sector, and BGO, a leading global real estate investment manager, have signed leading biotechnology company Nucleome Therapeutics as a landmark tenant at central Oxford’s first purpose-built commercial science scheme.
Inventa is the first commercial science scheme to be delivered in Oxford’s West End, the only innovation district within walking distance to Oxford train station and the city centre. The West End has a long-term pipeline of over 2 million sq ft of commercial and academic buildings and will play a crucial role in realising Oxford’s ambitions to become a global top three innovation cluster by 2040.
“Nucleome’s expansion, driven by the significant progress in identifying new drug candidates, has resulted in a need for larger office and lab space. We chose Inventa because of its central location, and Mission Street’s reputation for designing buildings that thoroughly accommodate the needs of life science companies. We are looking forward to being part of this exciting new science and innovation hub in central Oxford.” – Stephen Harrison, Chief Scientific Officer of Nucleome Therapeutics
Originally a spinout from Oxford University, Nucleome aims to address traditional drug discovery failure rates by derisking novel targets through proprietary genomics approaches. Nucleome will be relocating from its existing headquarters at the Oxford Science Park.
For more information please click here.
